Across TCGA pan-cancer cohorts, MIRLET7BHG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIRLET7BHG data layer compared with 23 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MIRLET7BHG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIRLET7BHG expression acts as an unfavorable survival marker.

KIRP are the cancer types where MIRLET7BHG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.144	0.693	<.001	35	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MIRLET7BHG tumor-vs-normal RNA expression · all MIRLET7BHG data types